南都电源近期首次公开发行股票实际募集资金净额2.87亿美元。

锦天城高级合伙人章晓洪代表浙江南都电源动力股份有限公司参与了本次上市。

同时，深圳市海普瑞药业也在深圳证券交易所中小企业板8.68亿美元成功上市，创造了沪深股市发行价的新高。

中伦律师事务所受聘担任海普瑞上市项目发行人律师，本项代表律师为苏敏、许志刚、邹晓冬。中伦律师为海普瑞上市项目已经跟踪服务超过10年

The Shenzhen stock exchange has recently seen some stellar debuts by domestic players – Shenzhen Hepalink’s US$868m IPO on the Shenzhen small and medium-sized enterprises board and Zhejiang Narada Power Source’s US$287m IPO on the Shenzhen Growth Enterprises Market board.

Shenzhen Hepalink, the world's largest maker of the blood-thinner heparin, recently launched its US$868m IPO, becoming the record holder of the highest IPO share price in China’s A-share market. Zhong Lun partners Su Min, Xu Zhigang and Zou Xiaodong facilitated the listing. The firm has been long-term legal advisor to the issuer since a decade ago.

Hepalink was founded in 1998 and primarily produces herapin, which is purified from pig intestines then made into a shot used to prevent blood clots in patients with heart conditions. The company is the only Chinese company accredited by the US Food and Drug Administration to export herapin.

Zhejiang Narada Power Source, which principally engages in the research, development, manufacturing and sale of chemical power sources and new energy products, is another another company to have sought to raise funds from listing on the Shenzhen board. Advised by AllBright partner Zhang Xiaohong, the firm’s debut raised about US$287m.

According to Dealogic, since January 2010 there have been nine IPOs in Shanghai raising some US$7.7bn and 59 in Shenzhen raising US$7.3bn.